Evolus has secured exclusive U.S. distribution rights to Profhilo, an IBSA hyaluronic acid injectable biostimulator, under a 15-year licensing agreement with no upfront payment. The deal signals Evolus's strategy to broaden its injectables footprint beyond Jeuveau (neuromodulator) and into the growing biostimulator category, where practices increasingly stack HA-based products alongside toxin and filler for volumization and collagen remodeling.
Injectables
Evolus Secures Exclusive U.S. License for Profhilo — 15-Year Term, No Upfront Fee
Injectable biotech adds hyaluronic acid biostimulator to portfolio; no upfront payment signals confidence in market adoption.
Evolus adds Profhilo to injectables portfolio under 15-year exclusive U.S. license with no upfront fee.
Profhilo's mechanism—high-concentration HA with minimal cross-linking, designed for superficial dermal placement and hydration-driven collagen stimulation—positions it as a complement to PLLA (Sculptra) and CaHA (Radiesse) in the biostimulator ladder. For Evolus, the zero-upfront structure reflects confidence in Profhilo's adoption trajectory and suggests aggressive go-to-market pricing through Evolus Rewards to capture medspa share from Allergan and Galderma's established HA portfolios.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.